These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

695 related items for PubMed ID: 18652557

  • 21. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
    Hebart H, Kanz L, Jahn G, Einsele H.
    Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
    [Abstract] [Full Text] [Related]

  • 22. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
    Mwintshi K, Brennan DC.
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
    [Abstract] [Full Text] [Related]

  • 23. Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy.
    Baillie GM.
    Am J Health Syst Pharm; 2006 Oct 01; 63(19 Suppl 5):S10-6. PubMed ID: 16990639
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.
    Boivin G, Goyette N, Gilbert C, Covington E.
    J Med Virol; 2005 Nov 01; 77(3):425-9. PubMed ID: 16173018
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients.
    Limaye AP.
    Semin Respir Infect; 2002 Dec 01; 17(4):265-73. PubMed ID: 12497543
    [Abstract] [Full Text] [Related]

  • 30. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.
    Singh N.
    J Clin Virol; 2006 Apr 01; 35(4):474-7. PubMed ID: 16406798
    [Abstract] [Full Text] [Related]

  • 31. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
    Chakrabarti S, Collingham KE, Osman H, Fegan CD, Milligan DW.
    Bone Marrow Transplant; 2001 Nov 01; 28(9):879-81. PubMed ID: 11781649
    [Abstract] [Full Text] [Related]

  • 32. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.
    Transplant Proc; 2007 Sep 01; 39(7):2228-30. PubMed ID: 17889146
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
    Avery RK, Arav-Boger R, Marr KA, Kraus E, Shoham S, Lees L, Trollinger B, Shah P, Ambinder R, Neofytos D, Ostrander D, Forman M, Valsamakis A.
    Transplantation; 2016 Oct 01; 100(10):e74-80. PubMed ID: 27495775
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.